Brokers Offer Predictions for VYGR FY2029 Earnings

Voyager Therapeutics, Inc. (NASDAQ:VYGR) – Research analysts at Leerink Partnrs issued their FY2029 earnings estimates for shares of Voyager Therapeutics in a research note issued to investors on Tuesday, May 6th. Leerink Partnrs analyst L. Nsongo expects that the company will earn ($1.17) per share for the year. The consensus estimate for Voyager Therapeutics’ current full-year earnings is ($0.91) per share.

Voyager Therapeutics (NASDAQ:VYGR) last announced its earnings results on Tuesday, May 6th. The company reported ($0.53) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.18). The business had revenue of $6.47 million during the quarter, compared to analysts’ expectations of $13.55 million. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%.

Several other equities research analysts also recently weighed in on VYGR. Wells Fargo & Company set a $10.00 price target on Voyager Therapeutics and gave the stock an “overweight” rating in a report on Wednesday, March 12th. Canaccord Genuity Group reduced their target price on shares of Voyager Therapeutics from $14.00 to $12.00 and set a “buy” rating for the company in a research note on Thursday, March 13th. HC Wainwright reiterated a “buy” rating and set a $30.00 price target on shares of Voyager Therapeutics in a research note on Tuesday, April 8th. Wedbush restated an “outperform” rating on shares of Voyager Therapeutics in a research report on Wednesday, March 12th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Voyager Therapeutics in a report on Wednesday, March 12th. One research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Voyager Therapeutics presently has an average rating of “Buy” and a consensus target price of $13.97.

Voyager Therapeutics Trading Down 5.5 %

Shares of VYGR stock opened at $3.24 on Thursday. The company has a market capitalization of $179.21 million, a P/E ratio of 4.56 and a beta of 0.95. The business’s 50 day moving average is $3.52 and its two-hundred day moving average is $4.93. Voyager Therapeutics has a twelve month low of $2.75 and a twelve month high of $9.55.

Insider Activity

In related news, CEO Alfred Sandrock sold 10,885 shares of the firm’s stock in a transaction that occurred on Wednesday, April 2nd. The stock was sold at an average price of $3.43, for a total value of $37,335.55. Following the completion of the transaction, the chief executive officer now directly owns 430,931 shares of the company’s stock, valued at $1,478,093.33. This trade represents a 2.46 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 6.39% of the company’s stock.

Institutional Trading of Voyager Therapeutics

Large investors have recently bought and sold shares of the company. Cubist Systematic Strategies LLC acquired a new position in shares of Voyager Therapeutics during the 4th quarter worth $29,000. Tower Research Capital LLC TRC grew its stake in Voyager Therapeutics by 133.4% in the 4th quarter. Tower Research Capital LLC TRC now owns 5,383 shares of the company’s stock valued at $31,000 after acquiring an additional 3,077 shares during the last quarter. Picton Mahoney Asset Management increased its holdings in Voyager Therapeutics by 71.1% during the 4th quarter. Picton Mahoney Asset Management now owns 5,883 shares of the company’s stock valued at $33,000 after acquiring an additional 2,444 shares in the last quarter. CWM LLC raised its position in Voyager Therapeutics by 856.3% during the first quarter. CWM LLC now owns 10,471 shares of the company’s stock worth $35,000 after acquiring an additional 9,376 shares during the last quarter. Finally, Oxford Asset Management LLP purchased a new stake in shares of Voyager Therapeutics in the fourth quarter valued at about $60,000. Institutional investors and hedge funds own 48.03% of the company’s stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.